Ligand Pharmaceuticals Incorporated (LGND)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | -22,606 | 11,942 | -25,503 | 78,895 | 8,550 |
| Total assets | US$ in thousands | 941,774 | 787,216 | 762,668 | 1,301,380 | 1,362,280 |
| Operating ROA | -2.40% | 1.52% | -3.34% | 6.06% | 0.63% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $-22,606K ÷ $941,774K
= -2.40%
Ligand Pharmaceuticals Incorporated's operating return on assets (ROA) has shown fluctuation over the past years. In 2020, the operating ROA was 0.63%, indicating that the company generated a modest return on its assets. This figure increased significantly to 6.06% by the end of 2021, reflecting improved operational efficiency and profitability.
However, the operating ROA took a downturn in 2022, dropping to -3.34%, which signifies that the company's operating income was insufficient to cover its assets. The following year, in 2023, Ligand Pharmaceuticals saw a slight recovery with an operating ROA of 1.52%, indicating a partial improvement in utilizing its assets to generate operating income.
By the end of 2024, the operating ROA decreased again to -2.40%, suggesting that the company faced challenges in generating profits from its assets. Overall, the fluctuating trend in Ligand Pharmaceuticals' operating ROA indicates varying levels of efficiency in utilizing its assets to generate operating income, reflecting potential operational and financial challenges.
Peer comparison
Dec 31, 2024